Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 19/20 | 0.55 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PDE1A | P54750 | 1/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13865835 | 0.95 | PDE9A (0.58) | PDE9APDE1CPDE1APDE1B | |
| SCHEMBL13865883 | 0.88 | PDE9A (0.53) | PDE9APDE1CPDE1B | |
| SCHEMBL4505702 | 0.85 | PDE9A (0.49) | PDE9APDE1CPDE1BHDAC1HDAC2 | |
| SCHEMBL13865901 | 0.83 | PDE9A (0.61) | PDE9APDE1CPDE1B | |
| SCHEMBL4498031 | 0.81 | PDE9A (0.48) | PDE9APDE1CPDE1BHDAC1HDAC2 | |
| SCHEMBL13865809 | 0.81 | PDE9A (0.54) | PDE9APDE1CPDE1B | |
| SCHEMBL4524011 | 0.81 | PDE9A (0.57) | PDE9APDE1CPDE1BHDAC1HDAC2 | |
| SCHEMBL13865836 | 0.79 | PDE9A (0.46) | PDE9APDE1CPDE1BHDAC1HDAC2 | |
| SCHEMBL4513098 | 0.79 | PDE9A (0.51) | PDE9APDE1CPDE1B | |
| SCHEMBL13865737 | 0.79 | PDE9A (0.54) | PDE9APDE1CPDE1BHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | PDE9A 13/4885PDE1C 190/4885MEN1 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.